Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Lupin Australia Pty Limited

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (288)
ARTG (239)
Prescription medicine registration (18)

Date

2024 (48)
2023 (47)
2022 (222)
2021 (8)
2020 (33)
2019 (21)
2018 (32)
2017 (11)
2016 (10)
2014 (27)
2013 (17)
2012 (2)
2011 (16)
2010 (19)
2009 (1)
2008 (21)
2007 (5)
2001 (1)
1991 (4)

Results for "[search-keyword]"

Search

Sponsor content

545 result(s) found, displaying 181 to 190

TENOFOVIR EMT LUPIN tenofovir disoproxil phosphate and emtricitabine 291mg/200mg film coated tablets Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
TENOFOVIR LUPIN tenofovir disoproxil phosphate 291 mg film-coated tablet Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
EZETIMIBE Lupin ezetimibe 10 mg tablet bottle (HDPE bottle with molecular sieve sachet) Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
EZETIMIBE Lupin ezetimibe 10 mg tablet bottle (HDPE bottle with stabilox) Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
EZETIMIBE Lupin ezetimibe 10 mg tablet blister pack (Cold form desiccant blister) Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
EZETIMIBE Lupin ezetimibe 10 mg tablet blister pack (Cold form Alu-Alu blister) Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
EZETIMIBE Lupin ezetimibe 10 mg tablet blister pack (PVC-Aclar blister) Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
TADALAFIL GENERICHEALTH tadalafil 5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
TADALAFIL GENERICHEALTH tadalafil 20 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
SITAGLIPTIN GH sitagliptin (as hydrochloride monohydrate) 50 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited

Pages

First page
Previous page
…
Page 15
Page 16
Page 17
Page 18
Current page 19
Page 20
Page 21
Page 22
Page 23
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.